Business
Lung Cancer Research Publication
Lung Cancer Research Publication.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 9140F Angle PLC 17 November 2015 \n \n\n\n\n\n\nFor immediate release \n \n\n\n17 November 2015\n\n\n\n\n \nANGLE plc \n(\"ANGLE\" or \"the Company\")\n \nCANCER RESEARCH UK MANCHESTER INSTITUTE REPORTS LUNG CANCER CTC ENRICHMENT USING PARSORTIX \n \nANGLE's Parsortix system \"… offers a unique combination of features making it suitable for routine clinical analysis of patient blood samples\" \n \n \nANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is delighted to announce that Cancer Research UK Manchester Institute (CRUK MI) has published highly encouraging results from its work in lung cancer patients using ANGLE's Parsortix system in the Royal Society of Chemistry's publication, Analyst. \n \nAnalyst publishes peer-reviewed analytical and bioanalytical research that reports premier fundamental discoveries and inventions, and the applications of those discoveries. The publication is available at http://www.angleplc.com/the-parsortix-system/download-files/\n \nLung cancer is the most common cancer in the world. More than 1.8 million cases of lung cancer were recorded in 2012, accounting for around 13 per cent of all new cancer cases (Source: World Cancer Research Fund International). Effective treatment for lung cancer is dependent on the cancer status which is determined through biopsy. However, where traditional solid biopsies are invasive and can harm the patient, liquid biopsies offer a non-surgical, patient-friendly alternative.\n \nGed Brady, Deputy and Genomics Leader within the Clinical & Experimental Pharmacology group at Cancer Research UK Manchester Institute, commented:\n\"The Parsortix system has a unique combination of features making it suitable for routine clinical analysis of patient blood samples. We have now incorporated the Parsortix workflow into multiple clinical trials and have been accumulating many hundreds of stored enriched samples that will be of immense value in our future CTC studies.\" \n \nANGLE's Founder and Chief Executive, Andrew Newland, added:\n\"This is our second peer-reviewed publication in a scientific journal and adds to the growing body of published evidence of Parsortix's performance as a liquid biopsy. The success in pilot studies in h...